CLAIMS

1. A peptide ligand specific for MT1-MMP, or a pharmaceutically acceptable salt thereof, wherein the peptide ligand comprises a polypeptide comprising at least three cysteine residues, separated by at least two loop sequences, and a molecular scaffold which forms covalent bonds with the cysteine residues of the polypeptide such that at least two polypeptide loops are formed on the molecular scaffold, wherein said molecular scaffold is 1,1',1''-(1,3,5-triazinane-1,3,5-triyl)triprop-2-en-1-one (TATA), characterised in that said peptide ligand comprises an amino acid sequence selected from:

CHPEWVSCEFHC (SEQ ID NO: 4);
CSHECALLFPKTC (SEQ ID NO: 5);
CFDECQLLFPKTC (SEQ ID NO: 6);
CLDECKLLFPKTC (SEQ ID NO: 7);
CREECMLLFPKTC (SEQ ID NO: 8);
CETECALLFPRSC (SEQ ID NO: 9);
CDVECRLLFPRSC (SEQ ID NO: 11);
CIDECRLLFPRSC (SEQ ID NO: 12);
CVRECALLFPKTC (SEQ ID NO: 13);
CV[HArg]ECALLFPKTC (SEQ ID NO: 14);
CVRECALLFPRTC (SEQ ID NO: 15);
CVRECALLFP[HArg]TC (SEQ ID NO: 16);
CV[HArg]ECALLFPATC (SEQ ID NO: 18);
CVAECALLFP[HArg]TC (SEQ ID NO: 19);
CVTECQLLFPKTC (SEQ ID NO: 20);
CRHECELLFPKTC (SEQ ID NO: 21);
CQRECALLFPKTC (SEQ ID NO: 22);
CVRECTLLFPKTC (SEQ ID NO: 23);
CTIECALLFPKTC (SEQ ID NO: 24);
CARECALLFPKTC (SEQ ID NO: 25);
CINECRLLFPKTC (SEQ ID NO: 26);
CYTECSLLFPKTC (SEQ ID NO: 27);
CHEECRLLFPKTC (SEQ ID NO: 28);
CLEECKLLFPKTC (SEQ ID NO: 29);
CIDECALLFPRTC (SEQ ID NO: 30);
CYEECRLLFPRTC (SEQ ID NO: 31);
CVRECRLLFPKTC (SEQ ID NO: 32);

CHIECALLFPKTC (SEQ ID NO: 33);
CKRECMLLFPKTC (SEQ ID NO: 34);
CYRECALLFPKTC (SEQ ID NO: 35);
CLTECALLFPKTC (SEQ ID NO: 36);
CEVECRLLFPKTC (SEQ ID NO: 37);
CEAECRLLFPKTC (SEQ ID NO: 38);
CVQECALLFPKTC (SEQ ID NO: 39);
CIRECSLLFPKTC (SEQ ID NO: 40);
CVTECALLFPKTC (SEQ ID NO: 41);
CVAECKLLFPKTC (SEQ ID NO: 42);
CVGECALLFPKTC (SEQ ID NO: 43);
CVVECALLFPKTC (SEQ ID NO: 44);
CVFECALLFPKTC (SEQ ID NO: 45);
CA[HArg]ECALLFP[HArg]TC (SEQ ID NO: 46);
CV[HArg]ECALLFA[HArg]TC (SEQ ID NO: 47);
CV[HArg]ECALL[1Nal]P[HArg]TC (SEQ ID NO: 49);
CV[HArg]ECALL[Cha]P[HArg]TC (SEQ ID NO: 50);
CV[HArg]ECALLF[Pip][HArg]TC (SEQ ID NO: 51);
CV[HArg]ECALLFP[HArg]SC (SEQ ID NO: 52);
CV[HArg]ECALLFP[HArg][HSer]C (SEQ ID NO: 53);
CV[HArg]ECALLF[HyP][HArg]TC (SEQ ID NO: 54);
CV[HArg]EC[Aib]LLFP[HArg]TC (SEQ ID NO: 55);
CV[HArg]ECAL[Nle]FP[HArg]TC (SEQ ID NO: 56);
CV[HArg]ECA[tBuAla]LFP[HArg]TC (SEQ ID NO: 57);
CV[HArg]ECA[Nle]LFP[HArg]TC (SEQ ID NO: 58);
CV[HArg]ECALL[4FlPhe]P[HArg]TC (SEQ ID NO: 61);
CV[HArg]ECAL[tBuGly]FP[HArg]TC (SEQ ID NO: 62);
CV[HArg]ECAL[Cha]FP[HArg]TC (SEQ ID NO: 63);
CV[HArg]ECALL[2Nal]P[HArg]TC (SEQ ID NO: 64);
CV[HArg]ECALLFP[HArg][HyV]C (SEQ ID NO: 65);
C[tBuGly][HArg]ECALLFP[HArg]TC (SEQ ID NO: 66);
CVEECALLFP[HArg]TC (SEQ ID NO: 67);
CV[HArg]ECA[Cpa]LFP[HArg]TC (SEQ ID NO: 68);
CV[HArg]ECA[Cba]LFP[HArg]TC (SEQ ID NO: 69);
CV[HArg]ECA[C5A]LFP[HArg]TC (SEQ ID NO: 70);
CV[HArg]ECA[Cha]LFP[HArg]TC (SEQ ID NO: 71);

CV[HArg]ECA[tBuGly]LFP[HArg]TC (SEQ ID NO: 72);
CV[HArg]ECALLF[Cis-HyP][HArg]TC (SEQ ID NO: 73);
CV[HArg]ECAL[Cpa]FP[HArg]TC (SEQ ID NO: 74);
CV[HArg]ECAL[C5A]FP[HArg]TC (SEQ ID NO: 75);
CV[HArg]ECA[tBuAla]LF[HyP][HArg]TC (SEQ ID NO: 76);
CV[HArg]ECA[tBuAla][tBuGly]F[HyP][HArg]TC (SEQ ID NO: 77);
C[tBuGly][HArg]ECA[tBuAla]LFP[HArg]TC (SEQ ID NO: 78);
CSSWDKLMCHPYC (SEQ ID NO: 79);
CPQECFYLPGHSLYC (SEQ ID NO: 81);
CPGECFYPPGHPLAC (SEQ ID NO: 82);
CPGECFYPTNHPLYC (SEQ ID NO: 83);
CPQECFYPIGHPLAC (SEQ ID NO: 84);
CPEECFYPPGHKLHC (SEQ ID NO: 85);
CPQECFYPPGHRLRC (SEQ ID NO: 86);
CPQECFYPPGHPYHC (SEQ ID NO: 87);
CPQECFYPSTHPLYC (SEQ ID NO: 88);
CPGECFYPSNHRLYC (SEQ ID NO: 89);
CPGECFYPPGHHLSC (SEQ ID NO: 91);
CPGECFYPPGHHLGC (SEQ ID NO: 92);
CPEECFYPPNHPLYC (SEQ ID NO: 93);
CPGECFYPPDHPLYC (SEQ ID NO: 94);
CPGECFYPPGHPLYC (SEQ ID NO: 95);
CPGECFYPPNHPFYC (SEQ ID NO: 96);
CPGECFYPPNHPLYC (SEQ ID NO: 97);
CPEECFYPPGHPLAC (SEQ ID NO: 98);
CWMECFYPPGHPLAC (SEQ ID NO: 99);
CFEECFYPPGHPLAC (SEQ ID NO: 100);
CPGECFYPPGHPLRC (SEQ ID NO: 101);
CPGECFYPPGHPREC (SEQ ID NO: 102);
CPGECFYPPGHRFHC (SEQ ID NO: 103);
CPGECFYPPGHRLYC (SEQ ID NO: 104);
CEEEFYPCGHPMHPC (SEQ ID NO: 108);
CDEQFYPCHHRLYSC (SEQ ID NO: 109);
CEEEFYPCGHPFHPC (SEQ ID NO: 110);
CLEQFYPCEHPLFSC (SEQ ID NO: 111);
CVEQFYPCGHRHYIC (SEQ ID NO: 112);

CEEQFYPCSHPLYTC (SEQ ID NO: 113);
CEEQFYPCNHPLNVC (SEQ ID NO: 114);
CEEEFYPCSHPLNPC (SEQ ID NO: 115);
CEEQFYPCGHKLSPC (SEQ ID NO: 116);
CPEQFYPCDHRLYIC (SEQ ID NO: 117);
CQEQFYPCNHPLSPC (SEQ ID NO: 118);
CDEQFYPCNHRLNTC (SEQ ID NO: 119);
CEEAFYPCHHPLYRC (SEQ ID NO: 120);
CEEQFYPCTHPLYVC (SEQ ID NO: 122);
CPEQFYPCTHRLYQC (SEQ ID NO: 123);
CEEQFYPCSHPLYRC (SEQ ID NO: 124);
CAEQFYPCDHPLYRC (SEQ ID NO: 125);
CAEEFYPCDHPLYRC (SEQ ID NO: 126);
CEEAFYPCNHPLYTC (SEQ ID NO: 127);
CAEAFYPCDHPLYVC (SEQ ID NO: 128);
CEEAFYPCSHPLFIC (SEQ ID NO: 129);
CEEAFYPCSHPLHPC (SEQ ID NO: 130);
CEEAFYPCSHPLFVC (SEQ ID NO: 131);
CEEQFYPCSHPLYSC (SEQ ID NO: 132);
CEEAFYPCEHPLYMC (SEQ ID NO: 133);
CEEQFYPCNHPLYMC (SEQ ID NO: 134); and
CLEQFYPCGDPRLC (SEQ ID NO: 135).

wherein Aib represents aminoisobutyric acid, C5a represents beta-cyclopentyl-L-alanine, Cba represents β-cyclobutylalanine, Cha represents 3-cyclohexyl-L-alanine, Cpa represents beta-cyclopropyl-L-alanine, 4FlPhe represents 4-fluoro-L-phenylalanine, HArg represents homoarginine, HyP represents hydroxyproline, HyV represents 3-hydroxy-L-valine, HSer represents homoserine, 1Nal represents 1-naphthylalanine, 2Nal represents 2-naphthylalanine, Nle represents norleucine, Pip represents pipecolic acid, tBuAla represents t-butyl-alanine, tBuGly represents t-butyl-glycine.

2. The peptide ligand as defined in claim 1, or a pharmaceutically acceptable salt thereof, wherein the peptide ligand comprises an amino acid sequence selected from:

CHPEWVSCEFHC (SEQ ID NO: 4);
CFDECQLLFPKTC (SEQ ID NO: 6);
CLDECKLLFPKTC (SEQ ID NO: 7);
CETECALLFPRSC (SEQ ID NO: 9);

CDVECRLLFPRSC (SEQ ID NO: 11);
CIDECRLLFPRSC (SEQ ID NO: 12);
CVRECALLFPKTC (SEQ ID NO: 13);
CV[HArg]ECALLFPKTC (SEQ ID NO: 14);
CVRECALLFPRTC (SEQ ID NO: 15);
CVRECALLFP[HArg]TC (SEQ ID NO: 16);
CV[HArg]ECALLFPATC (SEQ ID NO: 18);
CVAECALLFP[HArg]TC (SEQ ID NO: 19);
CVTECQLLFPKTC (SEQ ID NO: 20);
CQRECALLFPKTC (SEQ ID NO: 22);
CVRECTLLFPKTC (SEQ ID NO: 23);
CTIECALLFPKTC (SEQ ID NO: 24);
CARECALLFPKTC (SEQ ID NO: 25);
CINECRLLFPKTC (SEQ ID NO: 26);
CYTECSLLFPKTC (SEQ ID NO: 27);
CHEECRLLFPKTC (SEQ ID NO: 28);
CLEECKLLFPKTC (SEQ ID NO: 29);
CIDECALLFPRTC (SEQ ID NO: 30);
CYEECRLLFPRTC (SEQ ID NO: 31);
CVRECRLLFPKTC (SEQ ID NO: 32);
CHIECALLFPKTC (SEQ ID NO: 33);
CKRECMLLFPKTC (SEQ ID NO: 34);
CYRECALLFPKTC (SEQ ID NO: 35);
CEVECRLLFPKTC (SEQ ID NO: 37);
CEAECRLLFPKTC (SEQ ID NO: 38);
CVQECALLFPKTC (SEQ ID NO: 39);
CIRECSLLFPKTC (SEQ ID NO: 40);
CVTECALLFPKTC (SEQ ID NO: 41);
CVAECKLLFPKTC (SEQ ID NO: 42);
CVGECALLFPKTC (SEQ ID NO: 43);
CVVECALLFPKTC (SEQ ID NO: 44);
CVFECALLFPKTC (SEQ ID NO: 45);
CA[HArg]ECALLFP[HArg]TC (SEQ ID NO: 46);
CV[HArg]ECALLFA[HArg]TC (SEQ ID NO: 47);
CV[HArg]ECALL[1Nal]P[HArg]TC (SEQ ID NO: 49);
CV[HArg]ECALL[Cha]P[HArg]TC (SEQ ID NO: 50);

CV[HArg]ECALLF[Pip][HArg]TC (SEQ ID NO: 51);
CV[HArg]ECALLFP[HArg][HSer]C (SEQ ID NO: 53);
CV[HArg]ECALLF[HyP][HArg]TC (SEQ ID NO: 54);
CV[HArg]EC[Aib]LLFP[HArg]TC (SEQ ID NO: 55);
CV[HArg]ECAL[Nle]FP[HArg]TC (SEQ ID NO: 56);
CV[HArg]ECA[tBuAla]LFP[HArg]TC (SEQ ID NO: 57);
CV[HArg]ECA[Nle]LFP[HArg]TC (SEQ ID NO: 58);
CV[HArg]ECALL[4FlPhe]P[HArg]TC (SEQ ID NO: 61);
CV[HArg]ECAL[tBuGly]FP[HArg]TC (SEQ ID NO: 62);
CV[HArg]ECAL[Cha]FP[HArg]TC (SEQ ID NO: 63);
CV[HArg]ECALL[2Nal]P[HArg]TC (SEQ ID NO: 64);
CV[HArg]ECALLFP[HArg][HyV]C (SEQ ID NO: 65);
C[tBuGly][HArg]ECALLFP[HArg]TC (SEQ ID NO: 66);
CVEECALLFP[HArg]TC (SEQ ID NO: 67);
CV[HArg]ECA[Cpa]LFP[HArg]TC (SEQ ID NO: 68);
CV[HArg]ECA[Cba]LFP[HArg]TC (SEQ ID NO: 69);
CV[HArg]ECA[C5A]LFP[HArg]TC (SEQ ID NO: 70);
CV[HArg]ECA[Cha]LFP[HArg]TC (SEQ ID NO: 71);
CV[HArg]ECA[tBuGly]LFP[HArg]TC (SEQ ID NO: 72);
CV[HArg]ECALLF[Cis-HyP][HArg]TC (SEQ ID NO: 73);
CV[HArg]ECAL[Cpa]FP[HArg]TC (SEQ ID NO: 74);
CV[HArg]ECAL[C5A]FP[HArg]TC (SEQ ID NO: 75);
CV[HArg]ECA[tBuAla]LF[HyP][HArg]TC (SEQ ID NO: 76);
CV[HArg]ECA[tBuAla][tBuGly]F[HyP][HArg]TC (SEQ ID NO: 77);
C[tBuGly][HArg]ECA[tBuAla]LFP[HArg]TC (SEQ ID NO: 78);
CPQECFYLPGHSLYC (SEQ ID NO: 81);
CPGECFYPPGHPLAC (SEQ ID NO: 82);
CPQECFYPPGHRLRC (SEQ ID NO: 86);
CPEECFYPPNHPLYC (SEQ ID NO: 93);
CPGECFYPPDHPLYC (SEQ ID NO: 94);
CPGECFYPPGHPLYC (SEQ ID NO: 95);
CPGECFYPPNHPFYC (SEQ ID NO: 96);
CPGECFYPPNHPLYC (SEQ ID NO: 97);
CPEECFYPPGHPLAC (SEQ ID NO: 98);
CWMECFYPPGHPLAC (SEQ ID NO: 99);
CFEECFYPPGHPLAC (SEQ ID NO: 100);

CPGECFYPPGHPLRC (SEQ ID NO: 101);
CPGECFYPPGHPREC (SEQ ID NO: 102);
CPGECFYPPGHRFHC (SEQ ID NO: 103);
CPGECFYPPGHRLYC (SEQ ID NO: 104);
CDEQFYPCHHRLYSC (SEQ ID NO: 109);
CLEQFYPCEHPLFSC (SEQ ID NO: 111);
CEEQFYPCSHPLYTC (SEQ ID NO: 113);
CEEQFYPCNHPLNVC (SEQ ID NO: 114);
CEEEFYPCSHPLNPC (SEQ ID NO: 115);
CEEQFYPCGHKLSPC (SEQ ID NO: 116);
CPEQFYPCDHRLYIC (SEQ ID NO: 117);
CQEQFYPCNHPLSPC (SEQ ID NO: 118);
CDEQFYPCNHRLNTC (SEQ ID NO: 119);
CEEAFYPCHHPLYRC (SEQ ID NO: 120);
CEEQFYPCTHPLYVC (SEQ ID NO: 122);
CPEQFYPCTHRLYQC (SEQ ID NO: 123);
CEEQFYPCSHPLYRC (SEQ ID NO: 124);
CAEQFYPCDHPLYRC (SEQ ID NO: 125);
CAEEFYPCDHPLYRC (SEQ ID NO: 126);
CEEAFYPCNHPLYTC (SEQ ID NO: 127);
CAEAFYPCDHPLYVC (SEQ ID NO: 128);
CEEAFYPCSHPLFIC (SEQ ID NO: 129);
CEEAFYPCSHPLHPC (SEQ ID NO: 130);
CEEAFYPCSHPLFVC (SEQ ID NO: 131);
CEEQFYPCSHPLYSC (SEQ ID NO: 132);
CEEAFYPCEHPLYMC (SEQ ID NO: 133); and
CEEQFYPCNHPLYMC (SEQ ID NO: 134).

3. The peptide ligand as defined in claim 1, or a pharmaceutically acceptable salt thereof, wherein the peptide ligand comprises an amino acid sequence selected from:

CLDECKLLFPKTC (SEQ ID NO: 7);
CETECALLFPRSC (SEQ ID NO: 9);
CDVECRLLFPRSC (SEQ ID NO: 11);
CIDECRLLFPRSC (SEQ ID NO: 12);
CVRECALLFPKTC (SEQ ID NO: 13);
CV[HArg]ECALLFPKTC (SEQ ID NO: 14);

CVRECALLFPRTC (SEQ ID NO: 15);
CVRECALLFP[HArg]TC (SEQ ID NO: 16);
CV[HArg]ECALLFPATC (SEQ ID NO: 18);
CVAECALLFP[HArg]TC (SEQ ID NO: 19);
CVTECQLLFPKTC (SEQ ID NO: 20);
CQRECALLFPKTC (SEQ ID NO: 22);
CVRECTLLFPKTC (SEQ ID NO: 23);
CTIECALLFPKTC (SEQ ID NO: 24);
CARECALLFPKTC (SEQ ID NO: 25);
CINECRLLFPKTC (SEQ ID NO: 26);
CYTECSLLFPKTC (SEQ ID NO: 27);
CHEECRLLFPKTC (SEQ ID NO: 28);
CIDECALLFPRTC (SEQ ID NO: 30);
CYEECRLLFPRTC (SEQ ID NO: 31);
CVRECRLLFPKTC (SEQ ID NO: 32);
CHIECALLFPKTC (SEQ ID NO: 33);
CKRECMLLFPKTC (SEQ ID NO: 34);
CYRECALLFPKTC (SEQ ID NO: 35);
CEAECRLLFPKTC (SEQ ID NO: 38);
CVQECALLFPKTC (SEQ ID NO: 39);
CIRECSLLFPKTC (SEQ ID NO: 40);
CVTECALLFPKTC (SEQ ID NO: 41);
CVAECKLLFPKTC (SEQ ID NO: 42);
CVGECALLFPKTC (SEQ ID NO: 43);
CVVECALLFPKTC (SEQ ID NO: 44);
CVFECALLFPKTC (SEQ ID NO: 45);
CA[HArg]ECALLFP[HArg]TC (SEQ ID NO: 46);
CV[HArg]ECALLFA[HArg]TC (SEQ ID NO: 47);
CV[HArg]ECALL[Cha]P[HArg]TC (SEQ ID NO: 50);
CV[HArg]ECALLFP[HArg][HSer]C (SEQ ID NO: 53);
CV[HArg]ECALLF[HyP][HArg]TC (SEQ ID NO: 54);
CV[HArg]EC[Aib]LLFP[HArg]TC (SEQ ID NO: 55);
CV[HArg]ECA[tBuAla]LFP[HArg]TC (SEQ ID NO: 57);
CV[HArg]ECA[Nle]LFP[HArg]TC (SEQ ID NO: 58);
CV[HArg]ECALL[4FlPhe]P[HArg]TC (SEQ ID NO: 61);
CV[HArg]ECAL[tBuGly]FP[HArg]TC (SEQ ID NO: 62);

CV[HArg]ECAL[Cha]FP[HArg]TC (SEQ ID NO: 63);
CV[HArg]ECALLFP[HArg][HyV]C (SEQ ID NO: 65);
C[tBuGly][HArg]ECALLFP[HArg]TC (SEQ ID NO: 66);
CV[HArg]ECA[Cpa]LFP[HArg]TC (SEQ ID NO: 68);
CV[HArg]ECA[Cba]LFP[HArg]TC (SEQ ID NO: 69);
CV[HArg]ECA[C5A]LFP[HArg]TC (SEQ ID NO: 70);
CV[HArg]ECA[Cha]LFP[HArg]TC (SEQ ID NO: 71);
CV[HArg]ECALLF[Cis-HyP][HArg]TC (SEQ ID NO: 73);
CV[HArg]ECAL[Cpa]FP[HArg]TC (SEQ ID NO: 74);
CV[HArg]ECAL[C5A]FP[HArg]TC (SEQ ID NO: 75);
CV[HArg]ECA[tBuAla]LF[HyP][HArg]TC (SEQ ID NO: 76);
CV[HArg]ECA[tBuAla][tBuGly]F[HyP][HArg]TC (SEQ ID NO: 77);
C[tBuGly][HArg]ECA[tBuAla]LFP[HArg]TC (SEQ ID NO: 78);
CPQECFYPPGHRLRC (SEQ ID NO: 86);
CPEECFYPPNHPLYC (SEQ ID NO: 93);
CPGECFYPPDHPLYC (SEQ ID NO: 94);
CPGECFYPPGHPLYC (SEQ ID NO: 95);
CPGECFYPPNHPFYC (SEQ ID NO: 96);
CPGECFYPPNHPLYC (SEQ ID NO: 97);
CWMECFYPPGHPLAC (SEQ ID NO: 99);
CPGECFYPPGHPLRC (SEQ ID NO: 101);
CPGECFYPPGHPREC (SEQ ID NO: 102);
CPGECFYPPGHRFHC (SEQ ID NO: 103);
CPGECFYPPGHRLYC (SEQ ID NO: 104);
CDEQFYPCHHRLYSC (SEQ ID NO: 109);
CLEQFYPCEHPLFSC (SEQ ID NO: 111);
CEEQFYPCSHPLYTC (SEQ ID NO: 113);
CEEQFYPCNHPLNVC (SEQ ID NO: 114);
CEEEFYPCSHPLNPC (SEQ ID NO: 115);
CEEQFYPCGHKLSPC (SEQ ID NO: 116);
CPEQFYPCDHRLYIC (SEQ ID NO: 117);
CDEQFYPCNHRLNTC (SEQ ID NO: 119);
CEEAFYPCHHPLYRC (SEQ ID NO: 120);
CEEQFYPCTHPLYVC (SEQ ID NO: 122);
CPEQFYPCTHRLYQC (SEQ ID NO: 123);
CEEQFYPCSHPLYRC (SEQ ID NO: 124);

CAEQFYPCDHPLYRC (SEQ ID NO: 125);
CEEAFYPCNHPLYTC (SEQ ID NO: 127);
CAEAFYPCDHPLYVC (SEQ ID NO: 128);
CEEAFYPCSHPLFIC (SEQ ID NO: 129);
CEEAFYPCSHPLHPC (SEQ ID NO: 130);
CEEAFYPCSHPLFVC (SEQ ID NO: 131);
CEEQFYPCSHPLYSC (SEQ ID NO: 132); and
CEEQFYPCNHPLYMC (SEQ ID NO: 134).

4. The peptide ligand as defined in claim 1, or a pharmaceutically acceptable salt thereof, wherein the peptide ligand comprises an amino acid sequence selected from:
CVRECALLFPKTC (SEQ ID NO: 13);
CV[HArg]ECALLFPKTC (SEQ ID NO: 14);
CVRECALLFPRTC (SEQ ID NO: 15);
CVRECALLFP[HArg]TC (SEQ ID NO: 16);
CVAECALLFP[HArg]TC (SEQ ID NO: 19);
CARECALLFPKTC (SEQ ID NO: 25);
CINECRLLFPKTC (SEQ ID NO: 26);
CVRECRLLFPKTC (SEQ ID NO: 32);
CIRECSLLFPKTC (SEQ ID NO: 40);
CVTECALLFPKTC (SEQ ID NO: 41);
CVAECKLLFPKTC (SEQ ID NO: 42);
CVGECALLFPKTC (SEQ ID NO: 43);
CVVECALLFPKTC (SEQ ID NO: 44);
CVFECALLFPKTC (SEQ ID NO: 45);
CA[HArg]ECALLFP[HArg]TC (SEQ ID NO: 46);
CV[HArg]ECALLF[HyP][HArg]TC (SEQ ID NO: 54);
CV[HArg]EC[Aib]LLFP[HArg]TC (SEQ ID NO: 55);
CV[HArg]ECA[tBuAla]LFP[HArg]TC (SEQ ID NO: 57);
CV[HArg]ECA[Nle]LFP[HArg]TC (SEQ ID NO: 58);
CV[HArg]ECALL[4FlPhe]P[HArg]TC (SEQ ID NO: 61);
CV[HArg]ECAL[tBuGly]FP[HArg]TC (SEQ ID NO: 62);
CV[HArg]ECALLFP[HArg][HyV]C (SEQ ID NO: 65);
C[tBuGly][HArg]ECALLFP[HArg]TC (SEQ ID NO: 66);
CV[HArg]ECA[Cpa]LFP[HArg]TC (SEQ ID NO: 68);
CV[HArg]ECA[Cba]LFP[HArg]TC (SEQ ID NO: 69);

CV[HArg]ECA[C5A]LFP[HArg]TC (SEQ ID NO: 70);
CV[HArg]ECALLF[Cis-HyP][HArg]TC (SEQ ID NO: 73);
CV[HArg]ECA[tBuAla]LF[HyP][HArg]TC (SEQ ID NO: 76);
CV[HArg]ECA[tBuAla][tBuGly]F[HyP][HArg]TC (SEQ ID NO: 77);
C[tBuGly][HArg]ECA[tBuAla]LFP[HArg]TC (SEQ ID NO: 78);
CPGECFYPPGHRFHC (SEQ ID NO: 103);
CPGECFYPPGHRLYC (SEQ ID NO: 104); and
CEEAFYPCHHPLYRC (SEQ ID NO: 120).

5. The peptide ligand as defined in claim 1, or a pharmaceutically acceptable salt thereof, wherein the peptide ligand comprises an amino acid sequence selected from:
CVRECALLFPKTC (SEQ ID NO: 13);
CV[HArg]ECALLFPKTC (SEQ ID NO: 14);
CVRECALLFPRTC (SEQ ID NO: 15);
CVRECALLFP[HArg]TC (SEQ ID NO: 16);
CVRECRLLFPKTC (SEQ ID NO: 32);
CVTECALLFPKTC (SEQ ID NO: 41);
CVFECALLFPKTC (SEQ ID NO: 45);
CV[HArg]ECALLF[HyP][HArg]TC (SEQ ID NO: 54);
CV[HArg]ECA[tBuAla]LFP[HArg]TC (SEQ ID NO: 57);
CV[HArg]ECALL[4FlPhe]P[HArg]TC (SEQ ID NO: 61);
CV[HArg]ECA[Cpa]LFP[HArg]TC (SEQ ID NO: 68);
CV[HArg]ECA[C5A]LFP[HArg]TC (SEQ ID NO: 70);
CV[HArg]ECA[tBuAla]LF[HyP][HArg]TC (SEQ ID NO: 76);
C[tBuGly][HArg]ECA[tBuAla]LFP[HArg]TC (SEQ ID NO: 78); and
CPGECFYPPGHRLYC (SEQ ID NO: 104).

6. The peptide ligand as defined in claim 1, or a pharmaceutically acceptable salt thereof, wherein the peptide ligand comprises an amino acid sequence selected from:
CVRECALLFPKTC (SEQ ID NO: 13);
CVRECALLFPRTC (SEQ ID NO: 15);
CVFECALLFPKTC (SEQ ID NO: 45);
CV[HArg]ECA[tBuAla]LFP[HArg]TC (SEQ ID NO: 57);
CV[HArg]ECA[tBuAla]LF[HyP][HArg]TC (SEQ ID NO: 76); and
CPGECFYPPGHRLYC (SEQ ID NO: 104)

7. The peptide ligand as defined in claim 1, or a pharmaceutically acceptable salt thereof, wherein the peptide ligand comprises an amino acid sequence which is CV[HArg]ECA[tBuAla]LFP[HArg]TC (SEQ ID NO: 57).

8. The peptide ligand as defined in claim 1, or a pharmaceutically acceptable salt thereof, wherein the peptide ligand comprises an amino acid sequence selected from:

A-(SEQ ID NO: 4)-A (herein referred to as 17-116-01);
A-(SEQ ID NO: 5)-A (herein referred to as 17-120-00);
A-(SEQ ID NO: 6)-A (herein referred to as 17-120-01);
A-(SEQ ID NO: 7)-A (herein referred to as 17-120-02);
A-(SEQ ID NO: 8)-A (herein referred to as 17-120-03);
A-(SEQ ID NO: 9)-A (herein referred to as 17-120-04);
A-(SEQ ID NO: 11)-A (herein referred to as 17-120-07);
A-(SEQ ID NO: 12)-A (herein referred to as 17-120-08);
APPP-(SEQ ID NO: 13)-A (herein referred to as 17-120-09-T01);
QISP-(SEQ ID NO: 13)-A (herein referred to as 17-120-09-T02);
ALPP-(SEQ ID NO: 13)-A (herein referred to as 17-120-09-T03 and BCY1124);
Ac-ALPP-(SEQ ID NO: 13) (herein referred to as Ac-(17-120-09-T03) and BCY1125);
Sar3-ALPP-(SEQ ID NO: 13) (herein referred to as Sar3-A-(17-120-09-T03));
GPPP-(SEQ ID NO: 13)-A (herein referred to as 17-120-09-T04);
SPPP-(SEQ ID NO: 13)-A (herein referred to as 17-120-09-T05);
NPPP-(SEQ ID NO: 13)-A (herein referred to as 17-120-09-T06);
EPPP-(SEQ ID NO: 13)-A (herein referred to as 17-120-09-T07);
HPPP-(SEQ ID NO: 13)-A (herein referred to as 17-120-09-T08);
APNP-(SEQ ID NO: 13)-A (herein referred to as 17-120-09-T09);
APDP-(SEQ ID NO: 13)-A (herein referred to as 17-120-09-T10);
APLP-(SEQ ID NO: 13)-A (herein referred to as 17-120-09-T11);
APAP-(SEQ ID NO: 13)-A (herein referred to as 17-120-09-T12);
APHP-(SEQ ID NO: 13)-A (herein referred to as 17-120-09-T13);
Sar3-ALPP-(SEQ ID NO: 14) (herein referred to as Sar3-A-(17-120-09-T03) HArg2);
Sar3-ALPP-(SEQ ID NO: 15) (herein referred to as Sar3-A-(17-120-09-T03) Arg9);
Sar3-ALPP-(SEQ ID NO: 16) (herein referred to as Sar3-A-(17-120-09-T03) HArg9);
(B-Ala)-Sar10-ALPP-(SEQ ID NO: 18) (herein referred to as (B-Ala)-Sar10-A-(17-120-09-T03) HArg2 Ala9);
(B-Ala)-Sar10-ALPP-(SEQ ID NO: 19) (herein referred to as (B-Ala)-Sar10-A-(17-120-09-T03) Ala2 HArg9);

[Ac]LPP-(SEQ ID NO: 19) (herein referred to as BCY9938);
APMP-(SEQ ID NO: 20)-A (herein referred to as 17-120-10-T01);
APSP-(SEQ ID NO: 21)-A (herein referred to as 17-120-11-T01);
AALP-(SEQ ID NO: 22)-A (herein referred to as 17-120-12-T01);
ALDP-(SEQ ID NO: 23)-A (herein referred to as 17-120-13-T01);
ADRP-(SEQ ID NO: 24)-A (herein referred to as 17-120-14-T01);
ATQP-(SEQ ID NO: 25)-A (herein referred to as 17-120-15-T01);
SPPP-(SEQ ID NO: 25)-A (herein referred to as 17-120-15-T02);
ARHP-(SEQ ID NO: 26)-A (herein referred to as 17-120-16-T01);
ALPP-(SEQ ID NO: 27)-A (herein referred to as 17-120-17-T01);
A-(SEQ ID NO: 28)-A (herein referred to as 17-120-18);
A-(SEQ ID NO: 29)-A (herein referred to as 17-120-19);
A-(SEQ ID NO: 30)-A (herein referred to as 17-120-20);
A-(SEQ ID NO: 31)-A (herein referred to as 17-120-21);
APPP-(SEQ ID NO: 31)-A (herein referred to as 17-120-21-T01);
APSP-(SEQ ID NO: 32)-A (herein referred to as 17-120-22-T01);
PLPP-(SEQ ID NO: 32)-A (herein referred to as 17-120-22-T02);
APAP-(SEQ ID NO: 33)-A (herein referred to as 17-120-23-T01);
AVEP-(SEQ ID NO: 34)-A (herein referred to as 17-120-24-T01);
AEPA-(SEQ ID NO: 35)-A (herein referred to as 17-120-25-T01);
ASPP-(SEQ ID NO: 36)-A (herein referred to as 17-120-26-T01);
AAPP-(SEQ ID NO: 37)-A (herein referred to as 17-120-27-T01);
APPP-(SEQ ID NO: 38)-A (herein referred to as 17-120-28-T01);
AVPP-(SEQ ID NO: 39)-A (herein referred to as 17-120-29-T01);
SPPP-(SEQ ID NO: 40)-A (herein referred to as 17-120-30-T01);
HLPP-(SEQ ID NO: 41)-A (herein referred to as 17-120-31-T01);
RLPP-(SEQ ID NO: 41)-A (herein referred to as 17-120-31-T02);
APPP-(SEQ ID NO: 41)-A (herein referred to as 17-120-31-T03);
MPPP-(SEQ ID NO: 42)-A (herein referred to as 17-120-32-T01);
SPPP-(SEQ ID NO: 43)-A (herein referred to as 17-120-33-T01);
APPP-(SEQ ID NO: 44)-A (herein referred to as 17-120-34-T01);
APPP-(SEQ ID NO: 45)-A (herein referred to as17-120-35-T01);
[Ac]LPP-(SEQ ID NO: 46) (herein referred to as BCY9937);
[Ac]LPP-(SEQ ID NO: 47) (herein referred to as BCY9943);
[Ac]LPP-(SEQ ID NO: 49) (herein referred to as BCY9946);
[Ac]LPP-(SEQ ID NO: 50) (herein referred to as BCY9949);

[Ac]LPP-(SEQ ID NO: 51) (herein referred to as BCY9951);
[Ac]LPP-(SEQ ID NO: 52) (herein referred to as BCY9952);
[Ac]LPP-(SEQ ID NO: 53) (herein referred to as BCY9953);
[Ac]LPP-(SEQ ID NO: 54) (herein referred to as BCY9954);
[Ac]LPP-(SEQ ID NO: 55) (herein referred to as BCY9955);
[Ac]LPP-(SEQ ID NO: 56) (herein referred to as BCY9957);
[Ac]LPP-(SEQ ID NO: 57) (herein referred to as BCY9959);
[Ac]LYP-(SEQ ID NO: 57) (herein referred to as BCY12401);
[Ac]EYP-(SEQ ID NO: 57) (herein referred to as BCY12405);
[Ac]LPP-(SEQ ID NO: 58) (herein referred to as BCY9960);
[Ac]LPP-(SEQ ID NO: 61) (herein referred to as BCY9964);
[Ac]LPP-(SEQ ID NO: 62) (herein referred to as BCY9965);
[Ac]LPP-(SEQ ID NO: 63) (herein referred to as BCY9966);
[Ac]LPP-(SEQ ID NO: 64) (herein referred to as BCY10223);
[Ac]LPP-(SEQ ID NO: 65) (herein referred to as BCY10224);
[Ac]LPP-(SEQ ID NO: 66) (herein referred to as BCY11149);
[Ac]LPP-(SEQ ID NO: 67) (herein referred to as BCY11150);
[Ac]LPP-(SEQ ID NO: 68) (herein referred to as BCY11151);
[Ac]LPP-(SEQ ID NO: 69) (herein referred to as BCY11152);
[Ac]LPP-(SEQ ID NO: 70) (herein referred to as BCY11153);
[Ac]LPP-(SEQ ID NO: 71) (herein referred to as BCY11154);
[Ac]LPP-(SEQ ID NO: 72) (herein referred to as BCY11155);
[Ac]LPP-(SEQ ID NO: 73) (herein referred to as BCY11163);
[Ac]LPP-(SEQ ID NO: 74) (herein referred to as BCY11158);
[Ac]LPP-(SEQ ID NO: 75) (herein referred to as BCY11160);
[Ac]LYP-(SEQ ID NO: 76) (herein referred to as BCY12402);
[Ac]LYP-(SEQ ID NO: 77) (herein referred to as BCY12403);
[Ac]LYP-(SEQ ID NO: 78) (herein referred to as BCY12404).
A-(SEQ ID NO: 79)-A (herein referred to as 17-121-00)
A-(SEQ ID NO: 81)-A (herein referred to as 17-129-00);
SQT-(SEQ ID NO: 82)-A (herein referred to as 17-129-01-T01);
SMT-(SEQ ID NO: 82)-A (herein referred to as 17-129-01-T02);
SLV-(SEQ ID NO: 82)-A (herein referred to as 17-129-01-T03);
ISSYG-(SEQ ID NO: 82)-A (herein referred to as 17-129-01-T04);
ENITT-(SEQ ID NO: 82)-A (herein referred to as 17-129-01-T05);
A-(SEQ ID NO: 83)-A (herein referred to as 17-129-02);

A-(SEQ ID NO: 84)-A (herein referred to as 17-129-03);
A-(SEQ ID NO: 85)-A (herein referred to as 17-129-04);
A-(SEQ ID NO: 86)-A (herein referred to as 17-129-05);
A-(SEQ ID NO: 87)-A (herein referred to as 17-129-06);
A-(SEQ ID NO: 88)-A (herein referred to as 17-129-07);
A-(SEQ ID NO: 89)-A (herein referred to as 17-129-08);
A-(SEQ ID NO: 91)-A (herein referred to as 17-129-10);
A-(SEQ ID NO: 92)-A (herein referred to as 17-129-11);
L-(SEQ ID NO: 93)-HA (herein referred to as 17-129-12-T01);
T-(SEQ ID NO: 94)-NA (herein referred to as 17-129-13-T01);
Q-(SEQ ID NO: 95)-NA (herein referred to as 17-129-14-T01);
A-(SEQ ID NO: 95)-NVI (herein referred to as 17-129-14-T02);
N-(SEQ ID NO: 96)-NA (herein referred to as 17-129-15-T01);
D-(SEQ ID NO: 97)-RA (herein referred to as 17-129-16-T01);
SRM-(SEQ ID NO: 98)-A (herein referred to as 17-129-17-T01);
SRS-(SEQ ID NO: 98)-A (herein referred to as 17-129-17-T02);
RYMTR-(SEQ ID NO: 98)-A (herein referred to as 17-129-17-T03);
REE-(SEQ ID NO: 99)-A (herein referred to as 17-129-18-T01);
DNM-(SEQ ID NO: 99)-A (herein referred to as 17-129-18-T02);
QES-(SEQ ID NO: 99)-A (herein referred to as 17-129-18-T03);
ADY-(SEQ ID NO: 99)-A (herein referred to as 17-129-18-T04);
MAN-(SEQ ID NO: 100)-A (herein referred to as 17-129-19-T01);
SQN-(SEQ ID NO: 100)-A (herein referred to as 17-129-19-T02);
A-(SEQ ID NO: 101)-TVL (herein referred to as 17-129-20-T01);
A-(SEQ ID NO: 102)-SWL (herein referred to as 17-129-21-T01);
A-(SEQ ID NO: 103)-LTE (herein referred to as 17-129-22-T01);
A-(SEQ ID NO: 104)-YSE (herein referred to as 17-129-23-T01);
Ac-(SEQ ID NO: 104)-YSE (herein referred to as Ac(17-129-23-T01));
A-(SEQ ID NO: 108)-A (herein referred to as 17-126-06);
A-(SEQ ID NO: 109)-A (herein referred to as 17-126-07);
A-(SEQ ID NO: 110)-A (herein referred to as 17-126-08);
A-(SEQ ID NO: 111)-A (herein referred to as 17-126-09);
A-(SEQ ID NO: 112)-A (herein referred to as 17-126-10);
A-(SEQ ID NO: 113)-A (herein referred to as 17-126-18);
A-(SEQ ID NO: 114)-A (herein referred to as 17-126-19);
A-(SEQ ID NO: 115)-A (herein referred to as 17-126-20);

A-(SEQ ID NO: 116)-A (herein referred to as 17-126-21);
A-(SEQ ID NO: 117)-A (herein referred to as 17-126-22);
A-(SEQ ID NO: 118)-A (herein referred to as 17-126-23);
A-(SEQ ID NO: 119)-A (herein referred to as 17-126-24);
A-(SEQ ID NO: 120)-A (herein referred to as 17-126-25);
Ac-A-(SEQ ID NO: 120)-A (herein referred to as Ac-(17-126-25));
A-(SEQ ID NO: 122)-A (herein referred to as 17-126-27);
A-(SEQ ID NO: 123)-A (herein referred to as 17-126-28);
HSP-(SEQ ID NO: 124)-A (herein referred to as 17-126-30-T01);
GPH-(SEQ ID NO: 125)-A (herein referred to as 17-126-31-T01);
IHS-(SEQ ID NO: 126)-A (herein referred to as 17-126-32-T01);
WSP-(SEQ ID NO: 127)-A (herein referred to as 17-126-33-T01);
SHS-(SEQ ID NO: 127)-A (herein referred to as 17-126-33-T02);
DLH-(SEQ ID NO: 128)-A (herein referred to as 17-126-35-T01);
ANE-(SEQ ID NO: 129)-A (herein referred to as 17-126-36-T01);
AVW-(SEQ ID NO: 130)-A (herein referred to as 17-126-37-T01);
KVQ-(SEQ ID NO: 131)-A (herein referred to as 17-126-38-T01);
A-(SEQ ID NO: 132)-PDVA (herein referred to as 17-126-39-T01);
A-(SEQ ID NO: 133)-HQAA (herein referred to as 17-126-40-T01);
A-(SEQ ID NO: 134)-RENA (herein referred to as 17-126-41-T01); and
A-(SEQ ID NO: 135)-A (herein referred to as 17-126-11).

9. The peptide ligand as defined in any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutically acceptable salt is selected from the free acid or the sodium, potassium, calcium, ammonium salt.

10. The peptide ligand as defined in any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein the MT1-MMP is human MT1-MMP.

11. A drug conjugate comprising a peptide ligand or a pharmaceutically acceptable salt thereof as defined in any one of the preceding claims, conjugated to one or more effector and/or functional groups.

12. The drug conjugate as defined in claim 11, wherein the peptide ligand or pharmaceutically acceptable salt thereof is conjugated to one or more cytotoxic agents.

13. The drug conjugate as defined in claim 12, wherein said cytotoxic agent is selected from MMAE or DM1.

14. The drug conjugate as defined in claim 13, wherein the cytotoxic agent is MMAE and said conjugate additionally comprises a linker selected from: -PABC-Cit-Val-Glutaryl- or -PABC-cyclobutyl-Ala-Cit-βAla-, such as -PABC-Cit-Val-Glutaryl-, wherein PABC represents p-aminobenzylcarbamate.

15. The drug conjugate as defined in claim 11, wherein the one or more effector and/or functional group is a metal chelator.

16. The drug conjugate as defined in claim 15, wherein the metal chelator is complexed to a metal radioisotope.

17. The drug conjugate as defined in claim 16, wherein the metal radioisotope is selected from ^{64}Cu, ^{67}Ga, ^{68}Ga, ^{177}Lu, ^{90}Y, and ^{213}Bi.

18. A pharmaceutical composition which comprises the drug conjugate of any one of claims 12 to 17, in combination with one or more pharmaceutically acceptable excipients.

19. The pharmaceutical composition as defined in claim 18, which additionally comprises one or more therapeutic agents.

20. The drug conjugate as defined in any one of claims 12 to 17, for use in suppressing or treating solid tumour cancer.